The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted. The response of the Company is awaited.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Supriya Lifescience Limited to clarify why segment-wise details were not submitted along with its financial results for the quarter ended 31 December 2025. This clarification has been sought under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The company has not yet responded to the exchange's query. No details on the specific financials or business reasons behind the omission have been disclosed so far.
This is a routine procedural query from the exchange and is not expected to materially affect the stock. Investors should watch for the company's response to confirm full disclosure compliance, but such clarifications are usually resolved quickly without any business impact.